These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 606612)
1. [The in-vitro activity of fosfomycin and its pharmacokinetics in subjects with integral renal function, with renal failure and undergoing peritoneal and extracorporeal dialytic treatment]. De Rosa F; Enrico P; Buoncristiani U; Frongillo R G Ital Chemioter; 1977; 23(2):75-80. PubMed ID: 606612 [No Abstract] [Full Text] [Related]
3. Modality selection. Diaz-Buxo JA J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S112-7. PubMed ID: 11443757 [TBL] [Abstract][Full Text] [Related]
4. Dialysis for end-stage renal disease. Walker JA; Dodelson R; Eisinger RP J Med Soc N J; 1984 Dec; 81(12):1067-74. PubMed ID: 6595420 [No Abstract] [Full Text] [Related]
5. Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis. Van Biesen W; Verbeke F; Vanholder R Nephrol Dial Transplant; 2007 Jan; 22(1):53-8. PubMed ID: 17050633 [No Abstract] [Full Text] [Related]
6. [Dialysis treatment in children: methods, effects, complications]. Pela I; Materassi M; Lavoratti GC; Bartolozzi G Pediatr Med Chir; 1989; 11(3):237-41. PubMed ID: 2687815 [No Abstract] [Full Text] [Related]
7. Is it time to revisit residual renal function in haemodialysis? Ng TG; Johnson DW; Hawley CM Nephrology (Carlton); 2007 Jun; 12(3):209-17. PubMed ID: 17498114 [TBL] [Abstract][Full Text] [Related]
8. [Importance of fosfomycin urine and renal parenchyma levels in the treatment of urinary infections]. Asteriti M; Bellini G; Cartolari L; Zoni G Boll Chim Farm; 1978 Oct; 117(10):575-82. PubMed ID: 743353 [No Abstract] [Full Text] [Related]
9. Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro haemodialysis. Segall L; Covic A Nephrol Dial Transplant; 2007 Jan; 22(1):59-63. PubMed ID: 17099221 [No Abstract] [Full Text] [Related]
10. [Effect of sulfinpyrazone on peritoneal and renal clearance in patients with chronic renal failure treated by intermittent peritoneal dialysis]. Grzegorzewska A; Antoniewicz K; Kuźniak J; Zawadzka E Przegl Lek; 1990; 47(10):686-90. PubMed ID: 2089444 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of intravenous and intraperitoneal fosfomycin in continuous ambulatory peritoneal dialysis. Bouchet JL; Albin H; Quentin C; de Barbeyrac B; Vinçon G; Martin-Dupont P; Potaux L; Aparicio M Clin Nephrol; 1988 Jan; 29(1):35-40. PubMed ID: 3383462 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics of gentamycin sulfate in the healthy and in patients with terminal renal failure]. Dume T; Wetzels E; Herms W; Schröder E; Wahlig H Dtsch Med Wochenschr; 1971 Apr; 96(17):734-8 passim. PubMed ID: 4994837 [No Abstract] [Full Text] [Related]
15. [Renal function substitutes. Technical and logistic orientation of the treatment]. Legrain M; Rottembourg J Ann Med Interne (Paris); 1982; 133(8):611-24. PubMed ID: 6763488 [TBL] [Abstract][Full Text] [Related]
17. [Correlation of hematic, urinary and renal parenchymal fosfomycin concentrations]. Savoia D; Fontana G; Di Carlo R; Genazzani E G Ital Chemioter; 1977; 23(2):81-6. PubMed ID: 606613 [No Abstract] [Full Text] [Related]
18. Development of a computer-aided diagnosis system for a new modality of renal replacement therapy: an integrated approach combining both peritoneal dialysis and hemodialysis. Hamada H; Namoto S; Yamada R; Yamashita AC; Ishizaki M; Okamoto M Comput Biol Med; 2005 Dec; 35(10):845-61. PubMed ID: 16310010 [TBL] [Abstract][Full Text] [Related]
19. Dialysis--stands between deficit physiology and excess technology. Mukhopadhyay P J Indian Med Assoc; 2001 Jul; 99(7):354-5, 358. PubMed ID: 11881844 [No Abstract] [Full Text] [Related]